Prediction of repurposed drugs for treating lung injury in COVID-19 [version 2; peer review: 2 approved]
Background: Coronavirus disease (COVID-19) is an infectious disease discovered in 2019 and currently in outbreak across the world. Lung injury with severe respiratory failure is the leading cause of death in COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, t...
Main Authors: | Bing He, Lana Garmire |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2020-08-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/9-609/v2 |
Similar Items
-
ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs
by: Bing He, et al.
Published: (2023-02-01) -
Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19 [version 1; peer review: 2 approved]
by: Krishnaprasad Baby, et al.
Published: (2020-09-01) -
Multi-parametric characterization of drug effects on cells [version 2; peer review: 2 approved]
by: Yael Paran, et al.
Published: (2021-01-01) -
Predictive factors for hypothyroidy after hemithyroidectomy [version 2; peer review: 2 approved]
by: Boutheina Hammami, et al.
Published: (2022-12-01) -
Moral injury and the four pillars of bioethics [version 4; peer review: 2 approved]
by: Thomas F Heston, et al.
Published: (2023-12-01)